share_log

万泰生物(603392.SH):九价HPV疫苗拟纳入优先审评程序

Beijing Wantai Biological Pharmacy Enterprise (603392.SH): the nine-valent HPV vaccine is expected to be included in the priority review program.

Gelonghui Finance ·  Aug 12 06:30

On August 12th, Gelunhui reported that Beijing Wantai Biological Pharmacy Enterprise (603392.SH) announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd. collaborated with Xiamen University to research and develop a nine-valent vaccine (Escherichia coli) for human papillomavirus type 6/11/16/18/31/33/45/52/58 (referred to as 'nine-valent HPV vaccine'), which is on the priority list of drugs for review and approval by the National Medical Products Administration's drug evaluation center, with a public notice period of 7 days.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment